Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by DiaMedica Therapeutics Inc.
< Previous
1
2
Next >
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
August 07, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
August 01, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
July 11, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
July 01, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Announces $11.8 Million Private Placement
June 26, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
June 26, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
May 08, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
May 02, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
April 17, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
March 19, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
January 29, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
January 22, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
November 13, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
November 09, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
November 06, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
September 12, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
September 06, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
August 14, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
August 08, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference
July 18, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement
June 26, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Announces $37.5 Million Private Placement
June 21, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
June 21, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors
May 30, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results
May 15, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023
May 08, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer
April 11, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results
March 28, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023
March 20, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 13, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Tickers
DMAC
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.